BURLINGAME, Calif. - (Business Wire) Urigen Pharmaceuticals, Inc. (OTCBB: URGP,
http://www.urigen.com), a specialty pharmaceutical company focused on the development and commercialization of treatments for urological disorders, today announced that it will conduct a live webcast to provide a complete review of the Company
’s development programs at 11:00 a.m. EST on Thursday, March 13, 2008.
“Urigen welcomes this opportunity to review our pipeline with the investment community,” stated William J. Garner, President and CEO of Urigen Pharmaceuticals. “This webcast is our first step in describing the breadth and depth of our drug development pipeline, and in beginning to establish Urigen as the preferred specialty pharmaceutical company for urological disorders.”
By the end of this year, Urigen plans to have two programs in Phase II clinical trials and one in Phase III.
Urigen’s product development programs target significant unmet medical needs and major market opportunities in urology. URG101, targets painful bladder syndrome/interstitial cystitis, a condition that affects approximately 10.5 million women and men in North America. URG201, the Company’s second candidate, targets male hypogonadism, which has been estimated to effect 13 million men in the United States. Urigen’s URG301 is a treatment for urethritis, nocturia and acute urgency in female patients diagnosed with an overactive bladder.
The event will begin at 11:00 a.m. ET and will include a series of presentations by leading medical experts as well as Urigen management.
Presenters will include:
Lowell Parsons, M.D. - Professor of Urology, UCSD and Urigen Director
Grant Mulholland, M.D. - Professor and Chairman Emeritus, Thomas Jefferson Medical School
Dennis Giesing, PhD - Chief Scientific Officer, Urigen Pharmaceuticals
To access an audio webcast of this event, please go to the ‘Investors’ web page on Urigen’s website at http://www.urigen.com five minutes in advance of start time. Questions will be taken by email during the live webcast. A replay will also be available on demand, starting four hours after the webcast’s conclusion and until March 31, 2008.
About Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen’s product development programs target significant unmet medical needs and major market opportunities in urology. URG101 targets painful bladder syndrome/interstitial cystitis, which affects approximately 10.5 million men and women in North America. URG201 targets male hypogonadism, which has been estimated to effect 13 million men in the Untied States. Urigen’s URG301 project targets urethritis and acute urgency in patients diagnosed with an overactive bladder. For further information, please visit Urigen’s website at http://www.urigen.com.
Forward-Looking Statement
This press release may contain forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. For further risk factors associated with our Company, please review our SEC filings.
Urigen Pharmaceuticals, Inc.
Martin E. Shmagin, 650-259-0239
Chief Financial Officer
www.urigen.com
or
Thomas Redington
203-222-7399
212-926-1733
www.redingtoninc.com
